A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Bristol-Myers Squibb (BMS)

Status

Active, not recruiting

Conditions

Psoriasis

Treatments

Drug: Deucravacitinib

Biological: Any biologic treatment for psoriasis

Study type

Observational

Funder types

Industry

Identifiers

NCT06952465

IM011-227

Details and patient eligibility

About

The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting

Enrollment

2,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants with prescriptions in deucravacitinib or any biologics as comparator group during the indexing period.
Participants with at least one confirmed diagnosis of disease code for psoriasis within 12 months prior to the index date.
Aged 18 years or older at the index date

Exclusion criteria

Participants with prescription in deucravacitinib or any biologics as comparator group prior to the index date.
Participants with fewer than 12 months of available claim records prior to the index date.
Participants with no claims record within 1-year after the index date (no visit after the index date).
Specific for serious infection: Participants who had at least one disease code of hospitalized infection in the 60 days period before the index date.
Specific for malignancy: Participants who had at least one disease code of malignancy prior to the index date